REG - AstraZeneca PLC - Block listing Interim Review

AstraZenecaAnnouncement

02/12/2024 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241202:nRSB3915Oa&default-theme=true

RNS Number : 3915O  AstraZeneca PLC  02 December 2024

2 December 2024 15:05 GMT

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and
provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

 

Date: 2 December 2024

 

 Name of applicant:                                                                ASTRAZENECA PLC
 Name of scheme:                                                                   ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN;
                                                                                   ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED
                                                                                   SHARE OPTION SCHEME
 Period of return:                        From:                                    1 JUNE 2024                 To:                         30 NOVEMBER 2024
 Balance of unallotted securities under scheme(s) from previous return:            4,090,043
 Plus:  The amount by which the block scheme(s) has been increased since the       0
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         60,887
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        4,029,156

 

 Name of contact:              Hannah Tattersall
 Telephone number of contact:  +44 (0)20 3749 5000

 

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
 

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRFSUSAEELSELE